NCT03130348View on ClinicalTrials.gov

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 15, 2018

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
AmyloidosisImmunoglobulin Light Chain Deposition
Interventions
DRUG

Bortezomib

Given SC

DRUG

Dexamethasone

Given PO

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03130348 - Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis | Biotech Hunter | Biotech Hunter